An 18 Month Phase 2a Open Label, Randomized Study of Avastin, Lucentis, or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer)
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors OphthoTech Corporation
- 10 Jun 2017 Biomarkers information updated
- 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 13 Apr 2016 Status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.